This wiki has undergone a migration to Confluence found Here
Difference between revisions of "2017-08-10 Patient Care FHIR Call"
Jump to navigation
Jump to search
Line 257: | Line 257: | ||
* Should we focus on blood products initially? | * Should we focus on blood products initially? | ||
** Does MedicationAdministration fit? | ** Does MedicationAdministration fit? | ||
+ | * John said charting of meds/blood products is typically done using the same workflow | ||
+ | * Mike mentioned that blood products may require additional verification, but John said TPNs can also have similar requirements | ||
==== Decisions ==== | ==== Decisions ==== |
Revision as of 21:21, 10 August 2017
Contents
Meeting Information
Patient Care FHIR Resources Conference Call Location: Conference Call |
Date: 2017-08-10 Time: 5-6:30pm ET | ||
Facilitator | Michelle M Miller | Note taker(s) | Michelle M Miller |
Attendee | Name | Affiliation
| |
X | Elaine Ayres | NIH/Department of Clinical Research Informatics | |
X | Dave Carlson | VA | |
X | Stephen Chu | The Australian Digital Health Agency (ADHA) | |
Evelyn Gallego | EMI Advisors LLC | ||
X | Eric Haas | Haas Consulting | |
X | Rob Hausam | Hausam Consulting LLC | |
X | Laura Heermann-Langford | Intermountain Healthcare | |
X | Emma Jones | Allscripts | |
Russ Leftwich | InterSystems | ||
X | Tony Little | Optum 360 | |
X | Jay Lyle | Ockham Information Services LLC, VA | |
Russell McDonell | Telstra Health | ||
Lloyd McKenzie | Gevity (HL7 Canada) | ||
Larry McKnight | Cerner | ||
X | Michelle M Miller | Cerner | |
Lisa Nelson | Life Over Time Solutions | ||
Viet Nguyen | Lockheed Martin, Systems Made Simple | ||
M'Lynda Owens | Cognosante | ||
X | Mike Padula | The Children's Hospital of Philadelphia | |
Craig Parker | Intermountain Healthcare | ||
X | Joe Quinn | Optum | |
Simon Sum | Academy of Nutrition and Dietetics | ||
Iona Thraen | Dept of Veterans Affairs | ||
Serafina Versaggi | Dept of Veterans Affairs | ||
Buitendijk,Hans | Cerner | ||
JD Nolen | |||
Kenneth McCaslin | Accenture | ||
Lorraine Constable | |||
Patrick Loyd | |||
Riki Merrick | |||
X | Melva Peters | Gevity | |
X | John Hatem | ||
Jean Duteau | |||
X | Scott Robertson | ||
Jose Costa Teixeira | |||
Grahame Grieve | |||
X | Daniel Rutz | ||
Quorum Requirements Met: yes |
Agenda
Agenda Topics
- Agenda review
- Approve previous meeting minutes 2017-08-03_Patient_Care_FHIR_Call
- Motion: Stephen/Eric
- OO/PC/Pharmacy Joint Discussion
Supporting Information
- Tracker Issues - https://docs.google.com/a/lmckenzie.com/uc?id=0B285oCHDUr09Mzh3b09rMFhEV1E
- Resolve QA Warnings to have resource FMM > 0
- Resolve QA Information messages to achieve FMM = 3
- Maintain QA checklist
Minutes
Joint Discussion PC/OO/Pharmacy
Background
Recurring questions about how to handle biologically derived products (e.g. blood, tissue, organ) as well as procedures that are dosed (e.g. radiation-therapy, light therapy)
- GF#8458 Is a blood transfusion closer to a medication administration or a procedure, or something else?
- GF#12993 Please Create a NonMedicationAdministration object or an Administration object
- GF#12673 How to handle HCT/TP
- extension-device-din says
- The distinct identification code required by §1271.290(c) for a human cell, tissue, or cellular and tissue-based product (HCT/P) regulated as a device - which is a conditional, variable portion of the production identifier (PI) of a Unique device Identifier (UDI). If the content is from an ICCBBA-encoded UDI, the URI to use for the system is: http://hl7.org/fhir/NamingSystem/iccbba-din. GS1 and HIBCC formatted UDIs do not currently convey the DIN element.
- Note to balloters: The Orders and Observations Workgroup has not yet determined whether the Device resource will include Devices of Human (or other) Origin (tissue, blood, etc.) and so the need for Donation Identification number is currently being met through this extension. If it is determined a separate resource is to be used for Devices of Human (or other) Origin (tissue, blood, etc.) then this extension may be deprecated in the future. Feedback on this issue is welcome.
- Per Feb 2016 OO ListServ discussing GF#9449, proposed boundaries included
- Device: a manufactured item that is used in the provision of healthcare without being substantially changed through that activity. The device may be a medical or non-medical device
- Substance: A homogeneous material with a definite composition
- BiologicallyDerivedProduct: material extracted from a living mammalian organism or that is still living
- extension-device-din says
- 2017-04-13_Patient_Care_FHIR_Call
- NMDP (National Marrow Donor Program) and CIBTMR (Center for International Blood and Marrow Transplant Research) would like to participate in helping develop a new resource for transplant material
- It would include things like bone marrow, cord blood, peripheral blood stem cells - and any new resource could also address solid organs and blood transfusion although not part of the initial use case
- Align with scope of ISBT128, the purpose of which is: to provide standards and guidance for the coding and labeling of medical products of human origin (MPHO): blood, cellular therapy, tissues, regenerated tissue, milk, fecal microbiota, topical products of human origin, in vivo diagnostic MPHO, and organs for transplant, as well as those plasma derivatives for which ABO is relevant. (we may want to extend the scope to “biological origin” rather than limiting to “human origin”)
Discussion
- Topics
- blood transfusion
- blood products
- human cell, tissue, or cellular and tissue-based product (HCT/P)
- grafts
- bone marrow
- cord blood
- peripheral blood stem cells
- solid organs
- blood transfusion
- blood
- cellular therapy
- tissues
- regenerated tissue
- milk
- fecal microbiota
- topical products of human origin
- in vivo diagnostic MPHO
- organs for transplant
- plasma derivatives for which ABO is relevant
- What is being done in the real world?
- Should we focus on blood products initially?
- Does MedicationAdministration fit?
- John said charting of meds/blood products is typically done using the same workflow
- Mike mentioned that blood products may require additional verification, but John said TPNs can also have similar requirements
Decisions
Resource and Work Group Aligmment
- How to represent Blood products ( Device, Medications, New resource?)
- How to represent Transfusion requests (PR, MR, New resource?)
- How to represent Transfusion medicine (P, MA, MS, New resource?)
WGM Planning
Patient Care WGM agenda: PC_Sept_2017_WGM
SOAP / ClinicalImpression
- GF#12676 Guidance request for GP SOAP in FHIR (Alexander Henket) -
- https://chat.fhir.org/#narrow/stream/implementers/topic/ClinicalImpression
Adjourn
Adjourned at <hh:mm am/pm> <timezone>.
Meeting Outcomes
Actions
|
Next Meeting/Preliminary Agenda Items
|
© 2012 Health Level Seven® International. All rights reserved.